The company’s product is designed as an alternative to epinephrine auto-injectors to treat emergency allergic reactions.
Sandoz described Symjepi as an “affordable” alternative to EpiPens but did not disclose the product’s price.
“The Symjepi device is small in size and fits into the palm of your hand, with the goal of a simple-to-use application and intuitive, user-friendly design,” Sandoz president Carol Lynch said in prepared remarks.
“At Sandoz, we strive to reimagine medicine to offer the best care we can in all we do, and having heard from patients, caregivers and healthcare professionals about their eagerness for a new product, we are proud to be a part of the solution to a critical need in the U.S.,” Lynch added.
Last year, a number of epinephrine auto-injector manufacturers reported supply issues to the FDA.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.